GLP-1 receptor agonist: difference between revisions
Diff·revision 14 → 15·03:14, 20 Nov 2024
Difference between revision 14 and revision 15 of GLP-1 receptor agonist. 13 lines changed; the page grew by 1,583 bytes.
| Revision 14 — 17:03, 6 Nov 2024 TriumphThad (talk) rm the comparison to a compound with no published head-to-head data 6,539 bytes +232 | Revision 15 — 03:14, 20 Nov 2024 CiteBot (talk) bot: expand DOI to full citation 8,122 bytes +1,583 | ||
|---|---|---|---|
| 46 | Small-molecule agonists such as [[Orforglipron|orforglipron]] achieve oral bioavailability by abandoning the peptide backbone entirely. They are not subject to proteolysis and do not require an absorption enhancer, but they engage a different portion of the receptor and their efficacy relative to injected peptides remains under evaluation.{{r|frias2023}} | 46 | Small-molecule agonists such as [[Orforglipron|orforglipron]] achieve oral bioavailability by abandoning the peptide backbone entirely. They are not subject to proteolysis and do not require an absorption enhancer, but they engage a different portion of the receptor and their efficacy relative to injected peptides remains under evaluation.{{r|frias2023}} |
| 47 | 47 | ||
| + | 48 | == Clinical efficacy == | |
| + | 49 | Across the [[STEP trial programme|STEP]], [[SUSTAIN trial programme|SUSTAIN]] and [[SURPASS trial programme|SURPASS]] programmes the class has been assessed against placebo and against active comparators in both diabetic and non-diabetic populations. In people with obesity and without diabetes, weekly semaglutide 2.4 mg produced a mean weight change of −14.9% against −2.4% for placebo at 68 weeks.{{r|wilding2021}} In type 2 diabetes the same class produces glycated-haemoglobin reductions of roughly 1.0–1.8 percentage points, with the larger figures at the higher doses of the more recent agents.{{r|nauck2016}} | |
| + | 50 | ||
| + | 51 | Cardiovascular outcome trials have shown benefit for several members. The [[SELECT trial|SELECT]] trial reported a reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity but without diabetes, and the [[FLOW trial|FLOW]] trial reported slowing of kidney-disease progression.{{r|lincoff2023}} These are outcome findings for specific molecules at specific doses and are not properties of the class as a whole; extrapolation between members is not supported by the trial evidence. | |
| + | 52 | ||
| 48 | == References == | 53 | == References == |
| 49 | {{reflist}} | 54 | {{reflist}} |
| ⋮ | ⋮ | ||
| 52 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> | 57 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> |
| 53 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> | 58 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> |
| + | 59 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> | |
| 54 | <ref name="frias2023">Frías JP, Hsia S, Eyde S, et al. "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a phase 2 randomised trial." ''The Lancet'' 402(10400):472–483 (2023). PMID 37369232.</ref> | 60 | <ref name="frias2023">Frías JP, Hsia S, Eyde S, et al. "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a phase 2 randomised trial." ''The Lancet'' 402(10400):472–483 (2023). PMID 37369232.</ref> |
| + | 61 | ||
| + | 62 | == See also == | |
| + | 63 | * [[Glucagon-like peptide-1]] | |
| + | 64 | * [[GLP-1 receptor]] | |
| + | 65 | * [[Dual incretin agonist]] | |
| + | 66 | * [[Semaglutide]] | |
| + | 67 | * [[Liraglutide]] | |
| 55 | 68 | ||
| 56 | {{DEFAULTSORT:GLP-1 receptor agonist}} | 69 | {{DEFAULTSORT:GLP-1 receptor agonist}} |